Imaging of brain tumors in AIDS patients by means of dual-isotope thallium-201 and technetium-99m sestamibi single-photon emission tomography

Rosinda C. De La Peña, Leena Ketonen, Javier Villanueva-Meyer

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Our aim was to evaluate the use of dual-isotope thallium-201 (T1) and technetium-99m sestamibi (sestamibi) simultaneous acquisition in brain single-photon emission tomography (SPET) for the differentiation between brain lymphoma and benign central nervous system (CNS) lesions in AIDS patients. Thirty-six consecutive patients with enhancing mass lesions on magnetic resonance (MR) imaging were included in the study. SPET of the brain was performed to obtain simultaneous T1 and sestamibi images. Regions-of-interest were drawn around the lesion and on the contralateral side to calculate uptake ratios. The final diagnosis was reached by pathologic findings in 17 patients and clinical and/or MR follow-up in 19 patients. Of the 36 patients, 11 had brain lymphoma, 1 glioblastoma multiforme, 15 toxoplasmosis and 9 other benign CNS lesions. Correlation between SPET and the final diagnosis revealed in 10 true-positive, 23 true-negative, 1 false-positive and 2 false-negative studies. All patients with toxoplasmosis had negative scans. A patient with a purulent infection had positive scans. T1 and sestamibi scans were concordant in every lesion. The same lesions that took up T1 were also visualized with sestamibi. However, sestamibi scans showed higher lesion-to-normal tissue uptake ratios (3.7 ± 1.8) compared with those of T1 (2.3 ± 0.8, P < 0.002). Simultaneous acquisition of T1 and sestamibi can help differentiate CNS lymphoma from benign brain lesions in AIDS patients.

Original languageEnglish (US)
Pages (from-to)1404-1411
Number of pages8
JournalEuropean Journal Of Nuclear Medicine
Volume25
Issue number10
DOIs
StatePublished - Oct 21 1998

Fingerprint

Technetium Tc 99m Sestamibi
Thallium
Photons
Brain Neoplasms
Isotopes
Acquired Immunodeficiency Syndrome
Tomography
Brain
Lymphoma
Central Nervous System
Toxoplasmosis
Glioblastoma
Magnetic Resonance Spectroscopy
Magnetic Resonance Imaging

Keywords

  • AIDS
  • CNS lymphoma
  • Technetium-99m-sestamibi
  • Thallium-201

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Imaging of brain tumors in AIDS patients by means of dual-isotope thallium-201 and technetium-99m sestamibi single-photon emission tomography. / De La Peña, Rosinda C.; Ketonen, Leena; Villanueva-Meyer, Javier.

In: European Journal Of Nuclear Medicine, Vol. 25, No. 10, 21.10.1998, p. 1404-1411.

Research output: Contribution to journalArticle

@article{01cd3a1f6e5344d08b160d908d7475dd,
title = "Imaging of brain tumors in AIDS patients by means of dual-isotope thallium-201 and technetium-99m sestamibi single-photon emission tomography",
abstract = "Our aim was to evaluate the use of dual-isotope thallium-201 (T1) and technetium-99m sestamibi (sestamibi) simultaneous acquisition in brain single-photon emission tomography (SPET) for the differentiation between brain lymphoma and benign central nervous system (CNS) lesions in AIDS patients. Thirty-six consecutive patients with enhancing mass lesions on magnetic resonance (MR) imaging were included in the study. SPET of the brain was performed to obtain simultaneous T1 and sestamibi images. Regions-of-interest were drawn around the lesion and on the contralateral side to calculate uptake ratios. The final diagnosis was reached by pathologic findings in 17 patients and clinical and/or MR follow-up in 19 patients. Of the 36 patients, 11 had brain lymphoma, 1 glioblastoma multiforme, 15 toxoplasmosis and 9 other benign CNS lesions. Correlation between SPET and the final diagnosis revealed in 10 true-positive, 23 true-negative, 1 false-positive and 2 false-negative studies. All patients with toxoplasmosis had negative scans. A patient with a purulent infection had positive scans. T1 and sestamibi scans were concordant in every lesion. The same lesions that took up T1 were also visualized with sestamibi. However, sestamibi scans showed higher lesion-to-normal tissue uptake ratios (3.7 ± 1.8) compared with those of T1 (2.3 ± 0.8, P < 0.002). Simultaneous acquisition of T1 and sestamibi can help differentiate CNS lymphoma from benign brain lesions in AIDS patients.",
keywords = "AIDS, CNS lymphoma, Technetium-99m-sestamibi, Thallium-201",
author = "{De La Pe{\~n}a}, {Rosinda C.} and Leena Ketonen and Javier Villanueva-Meyer",
year = "1998",
month = "10",
day = "21",
doi = "10.1007/s002590050315",
language = "English (US)",
volume = "25",
pages = "1404--1411",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - Imaging of brain tumors in AIDS patients by means of dual-isotope thallium-201 and technetium-99m sestamibi single-photon emission tomography

AU - De La Peña, Rosinda C.

AU - Ketonen, Leena

AU - Villanueva-Meyer, Javier

PY - 1998/10/21

Y1 - 1998/10/21

N2 - Our aim was to evaluate the use of dual-isotope thallium-201 (T1) and technetium-99m sestamibi (sestamibi) simultaneous acquisition in brain single-photon emission tomography (SPET) for the differentiation between brain lymphoma and benign central nervous system (CNS) lesions in AIDS patients. Thirty-six consecutive patients with enhancing mass lesions on magnetic resonance (MR) imaging were included in the study. SPET of the brain was performed to obtain simultaneous T1 and sestamibi images. Regions-of-interest were drawn around the lesion and on the contralateral side to calculate uptake ratios. The final diagnosis was reached by pathologic findings in 17 patients and clinical and/or MR follow-up in 19 patients. Of the 36 patients, 11 had brain lymphoma, 1 glioblastoma multiforme, 15 toxoplasmosis and 9 other benign CNS lesions. Correlation between SPET and the final diagnosis revealed in 10 true-positive, 23 true-negative, 1 false-positive and 2 false-negative studies. All patients with toxoplasmosis had negative scans. A patient with a purulent infection had positive scans. T1 and sestamibi scans were concordant in every lesion. The same lesions that took up T1 were also visualized with sestamibi. However, sestamibi scans showed higher lesion-to-normal tissue uptake ratios (3.7 ± 1.8) compared with those of T1 (2.3 ± 0.8, P < 0.002). Simultaneous acquisition of T1 and sestamibi can help differentiate CNS lymphoma from benign brain lesions in AIDS patients.

AB - Our aim was to evaluate the use of dual-isotope thallium-201 (T1) and technetium-99m sestamibi (sestamibi) simultaneous acquisition in brain single-photon emission tomography (SPET) for the differentiation between brain lymphoma and benign central nervous system (CNS) lesions in AIDS patients. Thirty-six consecutive patients with enhancing mass lesions on magnetic resonance (MR) imaging were included in the study. SPET of the brain was performed to obtain simultaneous T1 and sestamibi images. Regions-of-interest were drawn around the lesion and on the contralateral side to calculate uptake ratios. The final diagnosis was reached by pathologic findings in 17 patients and clinical and/or MR follow-up in 19 patients. Of the 36 patients, 11 had brain lymphoma, 1 glioblastoma multiforme, 15 toxoplasmosis and 9 other benign CNS lesions. Correlation between SPET and the final diagnosis revealed in 10 true-positive, 23 true-negative, 1 false-positive and 2 false-negative studies. All patients with toxoplasmosis had negative scans. A patient with a purulent infection had positive scans. T1 and sestamibi scans were concordant in every lesion. The same lesions that took up T1 were also visualized with sestamibi. However, sestamibi scans showed higher lesion-to-normal tissue uptake ratios (3.7 ± 1.8) compared with those of T1 (2.3 ± 0.8, P < 0.002). Simultaneous acquisition of T1 and sestamibi can help differentiate CNS lymphoma from benign brain lesions in AIDS patients.

KW - AIDS

KW - CNS lymphoma

KW - Technetium-99m-sestamibi

KW - Thallium-201

UR - http://www.scopus.com/inward/record.url?scp=0031683442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031683442&partnerID=8YFLogxK

U2 - 10.1007/s002590050315

DO - 10.1007/s002590050315

M3 - Article

C2 - 9818280

AN - SCOPUS:0031683442

VL - 25

SP - 1404

EP - 1411

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - 10

ER -